Literature DB >> 23715683

Refractory nasopharyngeal carcinoma: positron emission tomography combined with computed tomography-guided 125I seed implantation therapy after repeated traditional radiochemotherapy.

Fujun Zhang1, Ketong Wu, Fei Gao, Weidong Zhang, Feng Shi, Chuanxing Li.   

Abstract

OBJECTIVE: To evaluate the feasibility of positron emission tomography combined with computed tomography (PET-CT)-guided (125)I seed implantation in the treatment of patients with refractory nasopharyngeal carcinoma after repeated traditional radiochemotherapy. STUDY
DESIGN: Case series with chart review.
SETTING: University medical center. SUBJECTS AND METHODS: A total of 26 patients (18 men, 8 women; mean age, 51.3 ± 10.8 years; totaling 53 lesions with an average diameter of 2.86 ± 1.61 cm) were treated by PET-CT-guided (125)I seed implantation. All of the patients received a PET-CT scan 2 months after the treatment. Follow-up was conducted for ~2 to 43 months (median, 28.2 months) to observe the local control rate, overall survival rate, and clinical complications.
RESULTS: The local control rates of refractory nasopharyngeal carcinoma after repeated traditional radiochemotherapy after 3, 6, 12, 24, and 36 months were 90.6% (48/53), 79.3% (42/53), 71.7% (38/53), 62.3% (33/53), and 56.6% (30/53), respectively. The overall 1-, 2-, and 3-year survival rates were 87.2%, 71.3%, and 56.5%, respectively, with a median survival time of 28.2 months. Of all patients, 19.2% (5/26) died of local recurrence and 15.4% (4/26) died of metastases. One patient died of hypertensive cerebral hemorrhage, and another patient died from cachexia and infection. The long-term complications included hyperpigmentation at operative sites (n = 5), insensible feeling on the lateral cheek (n = 2), dryness of the oral cavity (n = 1), and headache (n = 1).
CONCLUSION: PET-CT-guided (125)I seed implantation is an acceptable and feasible method for treating refractory nasopharyngeal carcinoma with minimal damage and few complications.

Entities:  

Keywords:  125I seed; PET-CT; nasopharyngeal carcinoma; radiochemotherapy; therapy

Mesh:

Substances:

Year:  2013        PMID: 23715683     DOI: 10.1177/0194599813491221

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  3 in total

1.  In vivo molecular imaging and radionuclide (131I) therapy of human nasopharyngeal carcinoma cells transfected with a lentivirus expressing sodium iodide symporter.

Authors:  Shuo Shi; Min Zhang; Rui Guo; Ying Miao; Jiajia Hu; Yun Xi; Biao Li
Journal:  PLoS One       Date:  2015-01-26       Impact factor: 3.240

2.  Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports.

Authors:  Chen Chen; Song-Ran Liu; Shu Zhou; Xiao-Hui Li; Xiao-Hui Wang; Ya-Lan Tao; Hui Chang; Wen-Wen Zhang; Wen-Fei Li; Si-Lang Zhou; Yun-Fei Xia
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

3.  Low-activity 125I implantation into VX2 tumor rabbits and quantitative evaluation of the precise therapeutic effect.

Authors:  Zheng Wang; Juan Wang; Yongyi Yao; Feng Wang; Qiang Fan; Ruifeng Zhao
Journal:  Exp Ther Med       Date:  2021-10-12       Impact factor: 2.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.